Cancer treatment and research communications最新文献

{"title":"An investigation into the manganese superoxide dismutase (MnSOD Val-9Ala) gene polymorphisms employing high-resolution melting in patients with gastric cancer: A preliminary study","authors":"Alireza Moradabadi ,&nbsp;Maryam Fekri-Soofiabadi ,&nbsp;Atefeh Soltani ,&nbsp;Shahriar Dabiri","doi":"10.1016/j.ctarc.2025.100942","DOIUrl":"10.1016/j.ctarc.2025.100942","url":null,"abstract":"<div><div>Background: Gastric cancer with complex carcinogenesis and a multi-factorial immunopathophysiology is well-known as the third life-threatening type of cancer in Asia. In this regard, it has been demonstrated that the role of Reactive Oxygen Species (ROS) in these processes should not be underestimated. Besides, mitochondrial Manganese Superoxide Dismutase (MnSOD) with antioxidant properties show protective effects against ROS. On the other hand, MnSOD catalyzes the dismutation of superoxide radicals to H2O2 and oxygen reactions. A replacement of T with C at nucleotide 47 (Val-9Ala) leads to a change in MnSOD nascent protein signal sequences and builds a relationship with gastric cancer. Therefore, the authors aimed at investigating the Single Nucleotide Polymorphisms (SNPs) in patients with gastric cancer by employing High-Resolution Melting.</div><div>Methodology: In order to investigate the (T/C) polymorphisms of MnSOD, the genomic DNA of 30 paraffin-embedded tissue samples were collected from patients with gastric cancer and 30 healthy people, respectively. An investigation was conducted into the T/C polymorphisms of MnSOD by employing High Resolution Melting (HRM) in different melting temperatures (Tm). Afterward, the sequencing was carried out.</div><div>Results: Our findings obtained from HRM methods confirmed the SNP genotypes in each group. It is worth mentioning that frequencies of Ala/Ala, Ala/Val, and Val/Val genotypes in MnSOD in the healthy group were 13 (43.3 %), 13 (43.3 %), and 4 (13.3 %), respectively. On the other hand, in the understudy case group, frequencies for the aforementioned genotypes were 5 (16.6 %), 16 (53.3 %), and 9 (30 %), respectively. Besides, the frequencies of the Ala allele in gastric cancer were reported to be 43 % and 54 % for healthy people. Frequencies for the Val allele in the studied case and the control groups were 44 % and 56 %, respectively. The sensitivity and the specificity of the HRM method in detecting MnSOD SNPs were reported to be 100 %.</div><div>Conclusion: by taking into account the contributing roles of MnSOD SNPs in the induction of gastric cancer, it is highly recommended to create collaboration among basic medical scientists, geneticists, gastroenterologists, medical laboratory scientists, pathologists, and hematologists for more promising results and improved outcome of the diagnosis. Accordingly, we conducted an investigation with diagnostic purposes into the frequencies in SNPs for patients with gastric cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100942"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144107590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns of patients with EGFR exon 20 insertion–mutated advanced NSCLC treated with amivantamab or mobocertinib after platinum-based chemotherapy: A multi-database cohort study","authors":"Alexander Spira ,&nbsp;Dexter Waters ,&nbsp;Tao Ran ,&nbsp;Pratyusha Vadagam ,&nbsp;Jinghua He ,&nbsp;Julie Vanderpoel ,&nbsp;Anjali Donnelly ,&nbsp;Iris Lin","doi":"10.1016/j.ctarc.2025.100944","DOIUrl":"10.1016/j.ctarc.2025.100944","url":null,"abstract":"<div><h3>Objective</h3><div>To describe characteristics, treatment patterns, and outcomes of patients with <em>EGFR</em> exon 20 insertion (exon20ins)-positive advanced or metastatic non–small cell lung cancer (NSCLC) who received amivantamab or mobocertinib monotherapy after platinum-based chemotherapy (PBC).</div></div><div><h3>Patients and Methods</h3><div>This retrospective longitudinal cohort study pooled electronic health records from the Flatiron Health (January 2011-August 2022), Ontada (January 2013-January 2023), and COTA (January 2010-December 2022) databases. Patients (≥20 years) with advanced or metastatic <em>EGFR</em> exon20ins NSCLC who received amivantamab or mobocertinib following PBC were included. Patient characteristics and treatment patterns were analyzed descriptively. Time to next treatment or death (TTNTD) and time to discontinuation (TTD) were assessed using Kaplan-Meier estimates.</div></div><div><h3>Results</h3><div>44 patients treated with amivantamab and 24 patients with mobocertinib after PBC met the selection criteria. Patient characteristics were consistent with previous studies. Most patients received amivantamab or mobocertinib as second-line (57 % and 50 %) or third-line (32 % and 33 %) therapy. The median TTNTD was 9.2 months for amivantamab and 4.2 months for mobocertinib. Fewer patients in the amivantamab cohort (43 %) experienced a TTNTD event than the mobocertinib cohort (63 %). The median TTD was 8.6 months for amivantamab and 2.3 months for mobocertinib, with a lower discontinuation rate in the amivantamab cohort (46 % vs 67 %).</div></div><div><h3>Conclusion</h3><div>Real-world patients with <em>EGFR</em> exon20ins NSCLC treated with amivantamab after PBC experienced median TTNTD and TTD consistent with the median progression-free survival observed in its registrational trial while patients treated with mobocertinib exhibited faster disease progression and a higher frequency of treatment discontinuation.</div></div><div><h3>MicroAbstract</h3><div>This retrospective study described patient characteristics, treatment patterns, and outcomes in patients with <em>EGFR</em> exon20ins-mutated advanced or metastatic NSCLC who received amivantamab or mobocertinib monotherapy after platinum-based chemotherapy. Real-world patients treated with amivantamab experienced TTNTD and TTD consistent with the median progression-free survival observed in its registrational trial, while patients treated with mobocertinib exhibited faster disease progression and a higher frequency of treatment discontinuation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100944"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144117111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the prognostic significance of vitamin D deficiency in pancreatic cancer: Disease progression and survival outcomes","authors":"Aladeen Alloubani,&nbsp;Baraa Abadalhaq,&nbsp;Amal Alshami,&nbsp;Diana Fakhory,&nbsp;Feras Abdalghani,&nbsp;Mallak Almasri,&nbsp;Maysa Alkouz","doi":"10.1016/j.ctarc.2025.100917","DOIUrl":"10.1016/j.ctarc.2025.100917","url":null,"abstract":"<div><h3>Background</h3><div>Pancreatic cancer remains one of the most aggressive malignancies with limited treatment options and poor survival rates. Vitamin D deficiency has been suggested to influence cancer progression and survival outcomes in various malignancies.</div></div><div><h3>Aim</h3><div>This study aimed to investigate the association between Vitamin D deficiency and disease progression as well as survival in patients diagnosed with pancreatic cancer.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted, including 151 patients diagnosed with pancreatic cancer between 2012 and 2022. Serum Vitamin D levels at the time of diagnosis were measured. Disease progression was evaluated through radiological assessments and clinical reports. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were analyzed using Kaplan-Meier survival curves and Cox proportional hazards regression models.</div></div><div><h3>Results</h3><div>Of the 151 patients, 84 (56 %) were identified as Vitamin D deficient at the time of diagnosis. The deficient group exhibited a significantly higher frequency of advanced-stage disease (stages III and IV) compared to the non-deficient group (<em>p</em> &lt; 0.05). During the follow-up period, 66 (78.6 %) of Vitamin <span>d</span>-deficient patients and 56 (84.8 %) of non-deficient patients experienced disease progression (<em>p</em> = 0.51). Moreover, Kaplan-Meier analysis showed a non-significant trend toward shorter median PFS (8.95 months vs. 9.27 months, <em>p</em> = 0.51) and OS (17.64 months vs. 19.05 months, <em>p</em> = 0.616) in the Vitamin <span>d</span>-deficient group.</div></div><div><h3>Conclusion</h3><div>Vitamin D deficiency is prevalent among patients with pancreatic cancer and appears to be associated with more advanced disease at diagnosis. Although a trend toward poorer survival outcomes was observed, the association between Vitamin D deficiency and OS/PFS did not reach statistical significance. Additional prospective studies are needed to confirm these findings and explore potential benefits of Vitamin D supplementation in pancreatic cancer management.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100917"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of upfront radiotherapy with immune checkpoint inhibitors for brain metastasis in non-small cell lung cancer","authors":"Yu Tanaka ,&nbsp;Hiroki Izumi ,&nbsp;Eri Sugiyama ,&nbsp;Tetsuya Sakai ,&nbsp;Yuji Shibata ,&nbsp;Kaname Nosaki ,&nbsp;Hibiki Udagawa ,&nbsp;Shigeki Umemura ,&nbsp;Yoshitaka Zenke ,&nbsp;Shingo Matsumoto ,&nbsp;Kiyotaka Yoh ,&nbsp;Tetsuo Akimoto ,&nbsp;Koichi Goto","doi":"10.1016/j.ctarc.2025.100937","DOIUrl":"10.1016/j.ctarc.2025.100937","url":null,"abstract":"<div><h3>Introduction</h3><div>The optimal timing of radiotherapy (RT) for asymptomatic brain metastasis (aBM) in patients with non-small cell lung cancer (NSCLC) without targetable oncogenic drivers treated with immune checkpoint inhibitors (ICIs) remains unclear. This study aimed to assess the efficacy and safety of upfront (U)-RT combined with ICIs for aBM.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed consecutive patients with aBM from NSCLC who received ICI-containing chemotherapy at National Cancer Center Hospital East between 2016 and 2021. The U-RT group was defined patients who received RT for aBM before or during the first ICI cycle, and the non-U-RT group otherwise.</div></div><div><h3>Results</h3><div>Of the 324 patients with NSCLC and aBM screened, 54 were enrolled, with 34 and 20 patients in the U-RT and non-U-RT groups, respectively. The median overall survival was 27.5 and 13.8 months (hazard ratio [HR] = 0.40, 95 % confidence interval [CI] 0.19–0.87), respectively, and median cranial progression-free survival was 9.2 and 6.0 months (HR = 0.50, 95 % CI 0.25–0.98), respectively, in the U-RT and non-U-RT groups. The U-RT group showed a significantly lower aBM progression rate than the non-U-RT group (<em>P</em> = 0.04). U-RT was an independent prognostic factor in the multivariate analysis using propensity score adjustment (HR = 0.42, 95 % CI 0.18–0.96). Although severe adverse events were observed in 47 % and 35 % of patients in the U-RT and non-U-RT groups, respectively, no treatment-related deaths occurred.</div></div><div><h3>Conclusions</h3><div>ICIs with U-RT demonstrated higher efficacy with acceptable tolerability for aBM than ICIs without U-RT. Our findings should be confirmed in future prospective trials.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100937"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study","authors":"Tomonori Makiguchi ,&nbsp;Hisashi Tanaka ,&nbsp;Kei Morikawa ,&nbsp;Aya Hirata ,&nbsp;Hidetoshi Itani ,&nbsp;Shigeru Tanzawa ,&nbsp;Kageaki Watanabe ,&nbsp;Hiroyuki Yasuda ,&nbsp;Kazuya Horiuchi ,&nbsp;Hideyuki Nakagawa ,&nbsp;Yoshitaka Seki ,&nbsp;Yoshiro Nakahara ,&nbsp;Kentaro Hayashi ,&nbsp;Nobumasa Takahashi ,&nbsp;Takeo Endo ,&nbsp;Akihiro Bessho ,&nbsp;Tetsuya Okano ,&nbsp;Kiyoshi Takeyama ,&nbsp;Akikazu Kawase ,&nbsp;Makoto Endo ,&nbsp;Nobuhiko Seki","doi":"10.1016/j.ctarc.2025.100952","DOIUrl":"10.1016/j.ctarc.2025.100952","url":null,"abstract":"<div><h3>Objectives</h3><div>Plasma-based testing with circulating cell-free DNA (cfDNA) is an active area of biomarker exploratory studies in patients with non-small cell lung cancer (NSCLC) harboring <em>EGFR</em> mutations. The Exosome-focused Translational Research for Afatinib study prospectively explored novel plasma biomarkers for afatinib monotherapy in patients with NSCLC harboring <em>EGFR</em> mutations using genomics, proteomics, epigenomics, and metabolomics. Herein, we present the results of the genomics part.</div></div><div><h3>Materials and Methods</h3><div>Clinical data of afatinib were matched with next generation sequencing (NGS)-based genomics data of cfDNA (<em>n</em> = 101) and extracellular vesicle DNA (evDNA) (<em>n</em> = 99) from pretreatment plasma samples.</div></div><div><h3>Results</h3><div>The detection sensitivity of cfDNA and evDNA mutations was 86 % (87/101) and 37 % (37/99), respectively. When cfDNA mutations were classified into tissue-matched (any <em>EGFR</em> mutations consistent with those identified in tissue) (<em>n</em> = 28), tissue-unmatched (<em>n</em> = 59), and mutation-undetected (<em>n</em> = 14) groups, cfDNA mutation status was a predictor of progression-free survival (PFS) (<em>p</em> &lt; 0.01) and overall survival (OS) (<em>p</em> &lt; 0.01). EvDNA mutation status was a predictor of OS (<em>p</em> &lt; 0.01) rather than PFS (<em>p</em> = 0.48). When the tissue-unmatched cfDNA group was subclassified into <em>EGFR</em>-related (<em>n</em> = 49) and <em>EGFR</em>-unrelated (<em>n</em> = 10) groups, the <em>EGFR</em>-unrelated group had a median PFS and 3-year OS rate of 31.2 months and 80.0 %, respectively. <em>EGFR</em>-unrelated and mutation-undetected cfDNA groups (<em>n</em> = 24) exhibited a median PFS and 3-year OS rate of &gt;30 months and &gt;80 %, respectively, with afatinib monotherapy.</div></div><div><h3>Conclusion</h3><div>This is the first large-scale prospective study of NGS-based concurrent testing for plasma cfDNA and evDNA mutations. The findings suggest that cfDNA mutation status is a promising plasma biomarker for afatinib monotherapy.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100952"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144203122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The symptom burden of women with a known risk of breast cancer receiving risk reducing medication","authors":"Meagan S. Whisenant ,&nbsp;Jessica Treviño Jones ,&nbsp;Anneliese O. Gonzalez ,&nbsp;Therese Bartholomew Bevers ,&nbsp;Kelly Brassil ,&nbsp;Darcy A. Ponce ,&nbsp;Sharvari Kamat ,&nbsp;Emily Solis ,&nbsp;Ann Maliackal ,&nbsp;Hannah Warlick ,&nbsp;Amie Walters ,&nbsp;Chloe Denham ,&nbsp;Loretta A. Williams","doi":"10.1016/j.ctarc.2023.100784","DOIUrl":"10.1016/j.ctarc.2023.100784","url":null,"abstract":"<div><h3>Background</h3><div>For the estimated 10 million women in the United States who meet the high-risk criteria for breast cancer, evidence-based interventions may reduce the risk of breast cancer by 50–65 %. Even with substantial evidence supporting preventive medication for risk reduction, there is significant lack of uptake and adherence. The purpose of this study was to characterize the experience of women at high risk for breast cancer and define the content domain for a patient-reported outcomes (PRO) measure of symptom burden from breast cancer risk and risk reducing medication.</div></div><div><h3>Methods</h3><div>Thirty women at high risk for breast cancer and receiving risk reducing medication participated in single qualitative interviews. Content analysis was used to identify the symptom burden. An expert panel review rated the relevance of symptoms identified in the qualitative interviews to establish the items for inclusion in a PRO symptom burden measure.</div></div><div><h3>Results</h3><div>Participants had a mean age of 54.6 years; 43.3 % self-identified as Hispanic and 20.0 % self-identified as Black. Content analysis found 20 symptoms related to both risk and preventive treatment, with 8 symptoms reported by ≥ 20 % of women. All women described distress related to their risk and preventive care. Treatment-related symptoms varied based on history of risk-reducing surgery and type of endocrine therapy. Women described symptom-related interference with relationships, work, enjoyment of life, and adherence to risk reducing medication.</div></div><div><h3>Conclusions</h3><div>Women with a known high risk of breast cancer and receiving preventive care experience a unique symptom burden including multiple symptoms and functional impact related to symptoms.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100784"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis","authors":"Jinhuan Xu ,&nbsp;Xiaoying Zhang ,&nbsp;Yun Li ,&nbsp;Fankai Meng ,&nbsp;Yicheng Zhang ,&nbsp;Miao Zheng","doi":"10.1016/j.ctarc.2025.100902","DOIUrl":"10.1016/j.ctarc.2025.100902","url":null,"abstract":"<div><h3>Background</h3><div>While chimeric antigen receptor T-cell (CAR T) therapy has shown promise in treating B-cell non-Hodgkin lymphoma, its efficacy is variable in patients with poor initial responses. This study investigates the efficacy and safety of zanubrutinib combined with CAR T therapy targeting CD19 in refractory/relapsed diffuse large B cell lymphoma (DLBCL).</div></div><div><h3>Methods</h3><div>We conducted a retrospective study of 17 patients with R/R DLBCL who received zanubrutinib combined with anti-CD19 CAR T-cell therapy. We assessed overall survival (OS) and progression-free survival (PFS) and conducted subgroup analyses. We also monitored CAR T-cell expansion by quantifying vector copy numbers (VCN). Safety and tolerability were assessed by documenting adverse events, including cytokine release syndrome and neurotoxicity.</div></div><div><h3>Results</h3><div>The median follow-up was 30 months (range, 4–36). The overall response rate(ORR) was 88.2 %, with 70.5 % achieving complete remission. At 24 months, the estimated PFS was 59 % (95 %CI, 40–88 %), and the OS was 71 % (95 %CI, 52–90 %). At 36 months, the estimated OS was 65 % (95 %CI, 46–92 %). Patients with non-elevated lactate dehydrogenase(LDH) levels showed a higher PFS probability (100 %) compared to those with elevated LDH (42 %, 95 %CI: 21 %-81 %) (log-rank, <em>p</em> = 0.071). The area under the receiver-operating characteristic (ROC) curve for peak CAR T-cell expansion was 0.773, suggesting an optimal cutoff at day 13 for enhancing survival (sensitivity 66.7 %, specificity 90.9 %; <em>p</em> = 0.07). Early peak expansion (before day 13) correlated with better PFS and OS (log-rank, <em>p</em> = 0.0018 and <em>p</em> = 0.0053, respectively). The total VCN AUC was 0.636, with a cutoff of 12,690 significantly predicting survival (sensitivity 83.3 %, specificity 72.7 %; <em>p</em> = 0.366). Kaplan-Meier analysis indicated statistically significant differences in OS for patients with VCN below 12,690 (log-rank, <em>p</em> = 0.017) in comparison to those exceeding 12,690, though trends in PFS did not reach statistical significance (log-rank, <em>p</em> = 0.12). Safety profiles indicated manageable cytokine release syndrome, with no severe neurotoxicity reported.</div></div><div><h3>Conclusions</h3><div>Zanubrutinib combined with CAR T-cell therapy offers an effective treatment option for patients with R/R DLBCL, enhancing response rates and survival. Detailed analysis of CAR T-cell expansion provides insight into the dynamics of cellular responses, underscoring the potential for tailored therapeutic approaches based on biological markers.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100902"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carfilzomib in relapsed/refractory multiple myeloma patients – real world evidence – experiences of the Croatian cooperative group for hematologic diseases (KROHEM)","authors":"Davor Galusic ,&nbsp;Josip Batinic ,&nbsp;Ivan Krecak ,&nbsp;Barbara Dreta ,&nbsp;Delfa Radic Kristo ,&nbsp;Mario Pirsic ,&nbsp;Goran Rincic ,&nbsp;Jasminka Sincic-Petricevic ,&nbsp;Toni Valkovic ,&nbsp;Milan Vujcic ,&nbsp;Marin Simunic ,&nbsp;Karla Misura Jakobac ,&nbsp;Martina Sedinic Lacko ,&nbsp;Klara Brcic ,&nbsp;Vlatka Perisa ,&nbsp;Fran Petricevic ,&nbsp;Dragana Grohovac ,&nbsp;Hrvoje Holik ,&nbsp;Martina Moric Peric ,&nbsp;Ivan Zekanovic ,&nbsp;Sandra Basic-Kinda","doi":"10.1016/j.ctarc.2025.100912","DOIUrl":"10.1016/j.ctarc.2025.100912","url":null,"abstract":"<div><h3>Background</h3><div>Carfilzomib-based regimens brought a significant improvement in the treatment of relapsed/refractory multiple myeloma (RRMM). Even though efficacy and safety profiles of carfilzomib are well-established in several clinical trials, there is limited real-world data with carfilzomib-based protocols. Here we present our real-world experience with carfilzomib-based regimens for treatment of patients with RRMM in Croatia.</div></div><div><h3>Methods</h3><div>Data on patients with RRMM starting carfilzomib-based protocols in the period between June 2019 and February 2023 was collected by retrospective chart review from 14 Croatian centres.</div></div><div><h3>Results</h3><div>A total of 119 patients with RRMM were included; median age was 66 years (range 45–83 years), 59 (49.6 %) were females, and the median number of previous lines of therapies was 2 (range 1–8). Triplet based regimen was treatment choice in 84 (70.6 %) and 35 (29.4 %) patients were treated with carfilzomib in combination with dexamethasone (Kd). Overall response rate was 61.7 %, with 20 patients (18.7 %) achieving complete response (CR). Median progression free survival (PFS) and overall survival (OS) for entire cohort were 9.4 and 13.2 months, respectively. Median PFS was 12.8 months and 4.1 months for the triplets and doublets, respectively; the corresponding median OS was 18.6 and 7.9 months, respectively. The most common adverse events were anemia and thrombocytopenia; 19 patients (16 %) experienced cardiovascular events.</div></div><div><h3>Conclusion</h3><div>This is the first study to analyze clinical outcomes of RRMM patients treated with carfilzomib-based regimens in Croatia. Carfilzomib-based regimens showed substantial efficacy and acceptable toxicity in RRMM, especially in earlier treatment lines and triplet combinations.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100912"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome-wide cell-free DNA methylation profiling in advanced stage ovarian cancer. Are we looking at the tumor or the patient's immune response to the tumor?","authors":"Caroline B. van den Berg ,&nbsp;Gatske M. Nieuwenhuyzen-de Boer ,&nbsp;Ingrid A. Boere ,&nbsp;Ruben G. Boers ,&nbsp;Joachim B. Boers ,&nbsp;Wilfred F.J. van-IJcken ,&nbsp;Maurice P.H.M. Jansen ,&nbsp;Tugce S. Kirmizitas ,&nbsp;Joost H. Gribnau ,&nbsp;Heleen J. van Beekhuizen","doi":"10.1016/j.ctarc.2025.100903","DOIUrl":"10.1016/j.ctarc.2025.100903","url":null,"abstract":"<div><div>The aim of this study was to identify differentially methylated regions in cell-free DNA (cfDNA) between healthy persons and patients with advanced stage ovarian cancer (ASOC) and to identify differences in cfDNA methylation before and after cytoreductive surgery. Plasma-derived cfDNA was analyzed by a high-throughput genome wide DNA methylation sequencing technique: MeD-seq. A training set of therapy naïve cfDNA samples of patients with ASOC (≥FIGO stage IIIB, n=10) was compared with cfDNA of healthy controls (n=10) to define a ASOC specific cfDNA methylation signature. A cumulative hypermethylation score was constructed and a validation set of pre- and postoperative samples of 39 patients were compared using this score. MeD-seq results of tumor tissue samples were correlated with cfDNA results. Patients with ASOC showed a clear distinct cfDNA methylation signature from healthy controls (p&lt;0.0001). This cfDNA-methylation signature resulted in preoperative hypermethylation scores (135; interquartile range 110–163) that were significantly higher than postoperative hypermethylation scores (91; interquartile range 76–101) (p&lt;0.001). The cfDNA methylation signature at baseline differed from tumor tissue and was more closely related to DNA methylation of immune-related cells (T-lymphocytes, neutrophil granulocytes, monocytes, and B-lymphocytes) than to ASOC tissue.</div><div>MeD-seq provides a promising method for genome wide methylation profiling of cfDNA. Patients with ASOC could clearly be distinguished from healthy controls and differed pre- and postoperatively.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100903"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1","authors":"M Sereno ,&nbsp;A Collazo-Lorduy ,&nbsp;Y Garitaonaindia ,&nbsp;D Gómez de Antonio ,&nbsp;J Baena Espinar ,&nbsp;C Aguado de la Rosa ,&nbsp;P Cruz Castellanos ,&nbsp;S Falagán Martínez ,&nbsp;LE Chara Valverde ,&nbsp;R López-Castro ,&nbsp;A López-Martin ,&nbsp;J Rubio-Pérez ,&nbsp;A Gómez Rueda ,&nbsp;C Traseira Puchol ,&nbsp;X Mielgo Rubio ,&nbsp;B Losada Vila ,&nbsp;J Rogado ,&nbsp;E Bernal Hertfelder ,&nbsp;L Gutiérrez Sainz ,&nbsp;JL Campo-Cañaveral ,&nbsp;E Casado Sáenz","doi":"10.1016/j.ctarc.2025.100910","DOIUrl":"10.1016/j.ctarc.2025.100910","url":null,"abstract":"<div><h3>Background</h3><div>The adoption of combined chemotherapy (CT) and immunotherapy (IO) has advanced neoadjuvant therapy (NA) for non-small cell lung cancer (NSCLC), but data on functional impacts are limited. This multicenter retrospective study evaluates respiratory function in NSCLC patients undergoing NA.</div></div><div><h3>Methods</h3><div>From 2020 to 2024, 186 patients treated with CT or CT-IO (anti-PD-1/PD-L1) were analyzed. Respiratory tests (DLCO, FEV1, FVC) pre- and post-NA were compared, alongside clinical, pathological, and surgical variables.</div></div><div><h3>Results</h3><div>Median age: 68; 66.6 % male; 93 % smokers/ex-smokers, histologies: Squamous and adenocarcinoma (46 % each), DLCO decline was greater in CT-IO vs. CT (-12.6 % vs. -7.8 %, <em>p</em> = 0.007) and CT-IO showed increased FEV1 (+3.8 % vs. -2.5 %, <em>p</em> = 0.001) and FVC (+3.7 % vs. -0.7 %, <em>p</em> = 0.003), surgery rate: 85.7 % (lobectomy most common at 83.3 %) and no differences in complications were found except for 9 immune-mediated events in CT-IO.</div></div><div><h3>Conclusions</h3><div>CT-IO impacts DLCO more but improves FEV1 and FVC compared to CT. These findings warrant further validation in prospective studies.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100910"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143825497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}